ライフサイエンスコーパス: substance abuse

1 sity, maternal prenatal stress, and lifetime substance abuse.

2 ss high rates of psychiatric comorbidity and substance abuse.

3 caffold for development into a treatment for substance abuse.

4 in a number of complex disorders, including substance abuse.

5 d in diverse psychiatric disorders including substance abuse.

6 in individuals with a history of alcohol or substance abuse.

7 for treatment of stress-triggered relapse in substance abuse.

8 lity measures that have been associated with substance abuse.

9 cesses, as well as psychiatric disorders and substance abuse.

10 itical in the etiology of mood disorders and substance abuse.

11 tem (CNS), including Parkinson's disease and substance abuse.

12 , facilitating behavioural reinforcement and substance abuse.

13 be damage and behavioral disorders including substance abuse.

14 striatal reward processing in the absence of substance abuse.

15 ire interventions to discourage this form of substance abuse.

16 and other disorders, as well as features of substance abuse.

17 rs (AUDs) constitute the most common form of substance abuse.

18 ute to the aetiology of major depression and substance abuse.

19 anxiety disorders, depression and co-morbid substance abuse.

20 ower rates of justice-system involvement and substance abuse.

21 f anxiety disorders, depression and comorbid substance abuse.

22 on may need review in patients with comorbid substance abuse.

23 s in medical specialties, mental health, and substance abuse.

24 ental suicide had higher rates of alcohol or substance abuse.

25 sed risk for maladaptive outcomes, including substance abuse.

26 factor for subsequent depressive illness and substance abuse.

27 nosing, treating and preventing this type of substance abuse.

28 may identify children at high risk for later substance abuse.

29 ed to some psychiatric conditions, including substance abuse.

30 , obsessive-compulsive disorder, and chronic substance abuse.

31 broader and longer-term pattern of multiple substance abuse.

32 have shown promise in preclinical models of substance abuse.

33 minorities, but less likely to abstain from substance abuse.

34 eation in severely suicidal patients without substance abuse.

35 ease risk for maladaptive outcomes including substance abuse.

36 ADHD), aggression, post-traumatic stress and substance abuse.

37 brain to other drugs and prime it for future substance abuse.

38 e health, mental health, HIV, and alcohol or substance abuse.

39 flect vulnerability of prodromal patients to substance abuse.

40 ptic plasticity, and have been implicated in substance abuse.

41 ol or other drugs highlight threats posed by substance abuse.

42 r the development of anxiety, depression and substance abuse.

43 environmental experiences such as stress and substance abuse.

44 ing, response disinhibition, aggression, and substance abuse.

45 current history of cocaine or other illicit substance abuse.

46 rable and individuals with AN protected from substance abuse?

47 based rates of unauthorised leave (2.4%) and substance abuse (1.6%) were low.

48 5) but decreased slightly when adjusting for substance abuse (1.71; 1.60-1.82).

49 disease (2.23; 2.08-2.39), and those without substance abuse (1.96; 1.82-2.11).

50 Major depression and alcohol or substance abuse 21 months after the parent's death were

51 mental and behavioural disorders (including substance abuse; 21.5% [95 UI 17.2-26.3] of YLDs), and m

52 3.8% died prematurely) and those with solely substance abuse (6.2%) compared with those without comor

53 to initiate ART (94.7%) or had uncontrolled substance abuse (66.0%).

54 uthorised leave were 5.9% and 98.4%; and for substance abuse 8.1% and 99.0%.

55 When compared with those with no substance abuse, abusing all three substances was associ

56 ly-history negative (FHN, N=31) healthy, non-substance-abusing adults completed an fMRI Go/No-Go task

57 Alcohol or substance abuse after transplantation is associated with

58 obsessive-compulsive disorder, anorexia, or substance abuse), along with their mates.

59 /3) receptors, may increase vulnerability to substance abuse, although whether this phenotype confers

60 Substance abuse and addiction are associated with an app

61 f illness, higher rates of lifetime comorbid substance abuse and anxiety disorder, more antisocial pe

62 rior treatment of a psychiatric condition or substance abuse and attention-deficit/hyperactivity diso

63 tive behaviors associated with FR, including substance abuse and compulsive exercise.

64 o a number of behavioral problems, including substance abuse and delinquent behaviors.

65 m substance use disorder can be divided into substance abuse and dependence (addiction).

66 Although the rates of substance abuse and dependence are similar to those of t

67 ecific etiological influences on measures of substance abuse and dependence.

68 ll other mental health conditions, including substance abuse and eating disorders, seem to be exacerb

69 s may help explain how stress contributes to substance abuse and how it can disinhibit automatic beha

70 ains (employment, education, marital status, substance abuse and income), each with a minimum of 0 an

71 Substance Abuse and Mental Health Services Administratio

72 s significantly influence susceptibility for substance abuse and mood disorders.

73 nucleus accumbens is critically involved in substance abuse and motivation, we sought to determine w

74 promising therapeutics for the treatment of substance abuse and neuropsychiatric disorders.

75 ine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders.

76 , specially compared with those referred for substance abuse and personality disorders.

77 by the model included both well-known (e.g., substance abuse and psychiatric disorders) and less conv

78 rs provides a unique opportunity to decrease substance abuse and reduce associated criminal behavior.

79 increase the susceptibility for the onset of substance abuse and related psychiatric disorders.

80 evaluate the association between recipient's substance abuse and renal transplant access in patients

81 ive responding, such as ADHD, mania, chronic substance abuse and schizophrenia.

82 ons for a range of research lines, including substance abuse and stress, both research domains in whi

83 triatal CREM mediates impulsivity related to substance abuse and suggest that CREM and its regulated

84 re EHR and PRO for capture of depression and substance abuse and their relationship to adherence to a

85 Subsequent incidents of substance abuse and unauthorised leave were coded indepe

86 validity of its specific risk estimates for substance abuse and unauthorised leave.

87 As a consequence, substance abuse and/or acute psychiatric problems are st

88 significantly so for those with co-occurring substance abuse and/or dependence.

89 s (such as anxiety, adjustment reactions, or substance abuse); and 495 (52%) had no mental health dia

90 but modestly related to persistence of mood, substance abuse, and anxiety disorders.

91 disorder, schizophrenia-spectrum disorders, substance abuse, and anxiety or somatoform disorders).

92 ected services across medical, mental health/substance abuse, and court/social service systems.

93 eased risk for recurrence, suicide attempts, substance abuse, and functional disability.

94 r adjustment for hepatitis C, renal disease, substance abuse, and hemoglobin level (HR, 1.25; 95% CI,

95 etime family history of bipolar disorder and substance abuse, and less history at baseline of severe

96 us psychological disorders are comorbid with substance abuse, and noradrenergic signaling in the bed

97 tion factors have been implicated in cancer, substance abuse, and other pathological conditions.

98 rental maladjustment (violence, criminality, substance abuse, and psychopathology), as well as econom

99 lence and other data on depression, anxiety, substance abuse, and psychotic syndromes, with emphasis

100 ed higher rates of anger attacks/aggression, substance abuse, and risk taking compared with women.

101 iatric diseases, including major depression, substance abuse, and schizophrenia.

102 to account as well as concomitant alcohol or substance abuse, and systemic shock.

103 s, such as in-utero and infant malnutrition, substance abuse, and traumatic experiences, appear to be

104 ighly prevalent disorders (major depression, substance abuse, anxiety disorders, and posttraumatic st

105 Alcohol and substance abuse are common and may lead to a need for so

106 Sleep disorders and substance abuse are highly comorbid and we have previous

107 tions between socioeconomic status (SES) and substance abuse are sometimes positive, the poor are som

108 includes measures of depression (PHQ-9) and substance abuse (ASSIST).

109 sed program was psychological treatments for substance abuse, associated with an HR of 0.75 (95% CI,

110 with a history of repeated social stress to substance abuse behaviors.

111 e drug-seeking and drug-taking are important substance-abuse behaviors that have been linked to alter

112 aving in patients with HIV, homelessness, or substance abuse, but not in others.

113 ts, temporary housing (homeless, shelter, or substance abuse center) was the only factor associated w

114 h were high in those with any psychiatric or substance abuse comorbidity (3.8% died prematurely) and

115 was small in schizophrenia patients without substance abuse comorbidity (8.5% of whom had at least 1

116 isk increase was minimal in patients without substance abuse comorbidity (adjusted odds ratio, 1.3; 9

117 he risk was mostly confined to patients with substance abuse comorbidity (adjusted odds ratio, 6.4; 9

118 he risk was mostly confined to patients with substance abuse comorbidity (of whom 27.6% committed an

119 ms of inattention but may also contribute to substance abuse comorbidity in ADHD.

120 The risk increase among those with substance abuse comorbidity was significantly less prono

121 marital and immigrant status) and mediators (substance abuse comorbidity) were measured at baseline.

122 medicine and family medicine: 1) integrating substance abuse competencies into training, 2) assigning

123 implicated in numerous neuropsychiatric and substance abuse conditions, but their spectral overlap w

124 s care for patients around mental health and substance abuse conditions, health behavior change, life

125 diagnostic categories assessed, psychoactive substance abuse conferred the highest risk for all-cause

126 Persons with chronic mental illness and/or substance abuse constitute 22% of the US population yet

127 ss this question in sober alcoholics and non-substance-abusing control subjects and show that immedia

128 recent research on the relationship between substance abuse, crime, violence and mental illness, and

129 wn to be associated with poor ART adherence (substance abuse; depression).

130 adjusting for co-occurring mental health and substance abuse diagnoses in follow-up regression models

131 ning (MFF) cluster (parental mental illness, substance abuse disorder, and criminality; family violen

132 [aOR], 1.35; 95% CI, 1.21-1.49), alcohol and substance abuse disorders (aOR, 1.34; 95% CI, 1.05-1.72)

133 the comorbidity between eating disorders and substance abuse disorders is high.

134 BN and those with substance abuse disorders may share dopamine D2 receptor

135 (22.3%-60.4%) of participants with 12-month substance abuse disorders received treatment for substan

136 exists a range of affective, psychotic, and substance abuse disorders that have been associated with

137 on (alcoholism) is one of the most prevalent substance abuse disorders worldwide.

138 estigated included organic mental disorders, substance abuse disorders, schizophrenia, mood disorders

139 cocaine addiction and a DSM-V criterion for substance abuse disorders, the molecular adaptations pro

140 nt avenue for advancing our understanding of substance abuse disorders.

141 cocaine addiction and a DSM-V criterion for substance abuse disorders.

142 ders, but less likely to have behavioral and substance abuse disorders.

143 veloping neuropsychiatric disease, including substance abuse disorders.

144 Tolerance is a DSM-V criterion for substance abuse disorders.

145 iseases with multiple phenotypes such as the substance abuse disorders.

146 pain management, inflammation, obesity, and substance abuse disorders.

147 attention-deficit hyperactivity disorder and substance abuse disorders.

148 are vulnerable to depression and alcohol or substance abuse during the second year after the loss.

149 play important roles in depression, anxiety, substance abuse, emesis, inflammatory pain, spinal nocic

150 strongly linked prior to a possible onset of substance abuse, emphasizing their potential role in the

151 its association with other variables such as substance abuse, environmental stressors, and history of

152 lthough depression frequently co-occurs with substance abuse, few individuals entering substance abus

153 mental health factors with other risks (eg, substance abuse, financial problems, relationship proble

154 MBASE searches (1966 to June 2008), national substance abuse guidelines from the United States and ot

155 Siblings of patients with depression and substance abuse had significantly increased fecundity (F

156 Comorbidity of mental disorders and substance abuse has now been recognized universally, and

157 Patients with psychiatric diseases and/or substance abuse have an increased risk for hepatitis C v

158 o exclude tuberculosis, and in patients with substance abuse having smear-negative specimens to exclu

159 tion, peripheral arterial disease, epilepsy, substance abuse, heart failure, nonmetastatic cancer, me

160 Substance abuse history was the strongest predictor of O

161 gender, education, schizophrenia diagnosis, substance abuse history, and geographic region.

162 f systemic and CNS inflammation in aging and substance-abusing HIV populations.

163 n of evidence-based treatments of adolescent substance abuse holds the potential to further enhance t

164 eive HIV care in the VA have higher rates of substance abuse, homelessness and unemployment than indi

165 ealth, including missed appointments, active substance abuse, homelessness, and unemployment are asso

166 findings may contribute to "protection" from substance abuse in AN.

167 Substance abuse in developing females may have significa

168 Improved treatment for substance abuse in forensic psychiatric patients and oth

169 Effectively targeting and treating active substance abuse in HIV treatment settings may provide a

170 Impulsivity shares high comorbidity with substance abuse in humans, and high impulsivity (HI) in

171 ental milestones, and later vulnerability to substance abuse in juvenile nonhuman primates.

172 A higher prevalence of chronic diseases and substance abuse in low-SES individuals versus high-SES i

173 Substance abuse in mentally ill forensic psychiatric pat

174 mmendations focused on improving training in substance abuse in primary care residency programs in in

175 strate for impulsive-antisocial behavior and substance abuse in psychopathy.

176 unction may contribute to the comorbidity of substance abuse in schizophrenia.

177 Recreational drug use leads to compulsive substance abuse in some individuals.

178 This review focuses on alcohol and substance abuse in the context of solid-organ transplant

179 rm cigarette smoking and problems with other substance abuse in this population.

180 Prevention and early education on substance abuse in young teens are critical in combating

181 luding HIV, AIDS, severe mental illness, and substance abuse) in the United States.

182 income inner-city communities, and engage in substance abuse, including intravenous and crack cocaine

183 Substance abuse increases an individual's vulnerability

184 Associations between demographics and substance abuse indicators and evidence of pharmaceutica

185 Substance abuse indicators were identified in 279 decede

186 nal activity, mental health, abstaining from substance abuse, interpersonal functioning, and parentin

187 Substance abuse is a major barrier in eradication of the

188 Substance abuse is a pressing problem with few therapeut

189 sociated neurocognitive disorders (HAND) and substance abuse is known to accelerate HIV disease progr

190 such as diet, physical activity, sleep, and substance abuse; it also reflects stable epigenetic modi

191 and suggest that a long duration of illness, substance abuse, low weight, and poor psychosocial funct

192 Vulnerability to depression, and perhaps substance abuse, may be preserved by balancing selection

193 Substance abuse, medical co-morbidities, and low (<15) M

194 and management of co-existing mental health, substance abuse (MHSA), and chronic pain (CP) conditions

195 bstance use disorder in some youngsters, and substance abuse might complicate the subsequent course o

196 of MSM risk-taking (e.g., poverty, sex work, substance abuse, misconceptions about transmission, stig

197 Composite International Diagnostic Interview-Substance Abuse Module as the criterion standard.

198 Composite International Diagnostic Interview-Substance Abuse Module), yielding Diagnostic and Statist

199 ychiatric disorders including schizophrenia, substance abuse, mood disorders, Alzheimer's disease, an

200 uninsured and have the highest prevalence of substance abuse, motor vehicle accidents, and sexually t

201 function in the brain increases the risk for substance abuse, obesity, attention deficit/hyperactivit

202 ioral symptoms (e.g., cognitive deficits and substance abuse) often precede the clinical diagnosis of

203 ourse of illness, but the impact of comorbid substance abuse on recovery from major depressive episod

204 ic stress disorder, depression, anxiety, and substance abuse) on this association.

205 t offending, and not largely attributable to substance abuse or antisocial personality disorder.

206 ICD symptoms, personal or family history of substance abuse or bipolar disorder, and a personality s

207 Adolescent substance abuse or dependence is largely a function of s

208 at 50% to 80% of prisoners have a history of substance abuse or dependence.

209 r co-occurring psychiatric disorders such as substance abuse or depression.

210 ical conditions but by confounding issues of substance abuse or homelessness.

211 In the EHR model, neither substance abuse (OR = 1.25; 95% CI = 0.70-2.21) nor depr

212 Conversely, in the PRO model, current substance abuse (OR = 2.78; 95% CI = 1.33-5.81) and curr

213 premorbid mood disorders, anxiety disorders, substance abuse, or alcohol abuse.

214 hose with neurologic disorders or psychosis, substance abuse, or brain metastasis were excluded.

215 xcluded those with a history of head injury, substance abuse, or clinical depression.

216 ing or new psychiatric disorders, alcohol or substance abuse, or eating disorders.

217 rlying psychiatric disorder, the presence of substance abuse, or even the use of certain psychiatric

218 llness trajectory, chronicity, medication or substance abuse, or in fact a combination of some or all

219 proposed to improve depressive symptoms and substance abuse outcomes.

220 acy in preclinical models of anxiety, cough, substance abuse, pain (spinal and peripheral), and urina

221 s in clinical domains are also discussed for substance abuse, Parkinson's disease, attention-deficit/

222 al abuse, parental arrest record), clinical (substance abuse, perceived threats), dispositional (age,

223 pical antidepressant receiving attention for substance abuse pharmacotherapy, and its action includes

224 have clinical utility for pain treatment and substance abuse pharmacotherapy.

225 l risk factors such as smoking, obesity, and substance abuse play a part but do not fully explain the

226 illness and lower rates of family history of substance abuse, prior suicide attempts, and anxious and

227 lizing problems, internalizing problems, and substance abuse problems, as well as for each of three c

228 o old or had nonhepatic comorbid conditions, substance abuse problems, or other psychosocial barriers

229 health conditions; a sad or depressed mood; substance abuse problems; medical problems; recent crise

230 t least one externalizing, internalizing, or substance abuse psychiatric problem (based on self- or p

231 Co-occurring substance abuse, psychosis, mania, and cognitive impairm

232 se is a major risk factor for mood, anxiety, substance abuse, psychotic, and personality disorders, a

233 ve class, carotid stenosis intervention, and substance abuse referral for alcohol.

234 higher incomes, younger ages, no testing at substance abuse rehabilitation centers, no recent syphil

235 esent potential targets for the treatment of substance abuse relapse, a psychiatric condition perpetu

236 ted factors and 1 only endorsed alcohol- and substance abuse-related factors; however, 7 classes of d

237 elplessness tests in rats without exhibiting substance abuse-related, gating, and sedative side effec

238 However, the ADHD-substance abuse relationship often disappears when co-oc

239 lective antagonists and partial agonists for substance abuse remains critically important but will al

240 communities may have with mental health and substance abuse research.

241 usual, which included a handout and list of substance abuse resources (n = 433).

242 vational interviewing, a handout and list of substance abuse resources, and an attempted 10-minute te

243 Substance abuse results in adverse social and profession

244 e curve=.659, p<.05, 95% CI .531, .786); the substance abuse risk estimate predicted its outcome with

245 oviders caring for persons with a history of substance abuse, risk-taking behavior, or suicidal ideat

246 tanding psychiatric disorders, in particular substance abuse, schizophrenia, and the potential antide

247 s in academic medical centers, and 5) making substance abuse screening and management routine care in

248 rences in the burden of chronic diseases and substance abuse seem to have major importance in explain

249 Increases in spending on mental health and substance abuse services after implementation of Oregon'

250 enditures per enrollee for mental health and substance abuse services attributable to parity were pos

251 ctions on how plans manage mental health and substance abuse services can improve insurance protectio

252 and visit limitations for mental health and substance abuse services that are not imposed on medical

253 ive parity on spending for mental health and substance abuse services.

254 ars despite minimal use of mental health and substance abuse services.

255 factors, as well as reducing tobacco use and substance abuse, should be leading priorities in the med

256 ructive behavior, referral should be made to substance abuse specialists.

257 primary and substance-induced disorders, in substance-abusing subjects.

258 association was attenuated by adjustment for substance abuse, suggesting a mediating effect.

259 ta-analysis of five GABAA receptor genes and substance abuse support their involvement (with the best

260 use competencies into training, 2) assigning substance abuse teaching the same priority as teaching a

261 isposing factors for anxiety, depression, or substance abuse; that they play a key organizing role du

262 obiology contributes to eating disorders and substance abuse, this review focused on imaging studies

263 as the contribution of chronic diseases and substance abuse to differences in bacteremia risk.

264 ersons with mental illness and/or alcohol or substance abuse to obtain firearms.

265 in the pathogenesis of HIV-1 resulting from substance abuse to provide a better understanding for th

266 involving mental health, internal medicine, substance abuse treatment and internal medicine are cruc

267 lunteers recruited in the community and from substance abuse treatment centers included 6000 African

268 nary models such as community-based clinics, substance abuse treatment clinics, and specialized hospi

269 havioral therapy for depression delivered by substance abuse treatment counselors.

270 ating primary healthcare, mental health, and substance abuse treatment facilities, and highlights net

271 th substance abuse, few individuals entering substance abuse treatment have access to effective depre

272 nt depressive symptoms receiving residential substance abuse treatment is associated with improved de

273 s (n = 89; women n = 55) who volunteered for substance abuse treatment performed a Go/NoGo task while

274 not complete a 12-week cognitive behavioral substance abuse treatment program.

275 st drug use patterns among patients entering substance abuse treatment programs across the country wh

276 pioid addiction among patients presenting at substance abuse treatment programs.

277 April 15, 2013, at 2 academic health center substance abuse treatment research sites.

278 e used data from the 2009 National Survey of Substance Abuse Treatment Services public use file and t

279 in source of data was the National Survey of Substance Abuse Treatment Services, which provides facil

280 ty law on expenditures for mental health and substance abuse treatment services.

281 challenges to traditional mental health and substance abuse treatment systems.

282 Tailoring substance abuse treatment to specific needs of incarcera

283 ffectiveness trial that compared residential substance abuse treatment with residential treatment plu

284 ogy and behavior to inform research aimed at substance abuse treatment.

285 oid agonist therapy and improves outcomes of substance abuse treatment.

286 tance use disorder among women in outpatient substance abuse treatment.

287 Secondary outcomes were admission to substance abuse treatment; ASI composite scores for medi

288 rug-diversion investigators, poison centers, substance-abuse treatment centers, and college students.

289 , with consequences for scientific research, substance-abuse treatment, and public policy.

290 Relapse is highly prevalent following substance abuse treatments, highlighting the need for im

291 addition, the integration of evidence-based substance-abuse treatments into juvenile drug court enha

292 l in relationships, and (4) partner factors (substance abuse, unemployment, and infidelity).

293 ple, notably lower educational achievements, substance abuse, violence, and poor reproductive and sex

294 nagement of traditional CAD risk factors and substance abuse, vitamin D deficiency should be evaluate

295 EHR vs PRO diagnosis of current substance abuse was 13% (n = 99) vs 6% (n = 45) (P < .00

296 Increased vulnerability to substance abuse was also demonstrated.

297 education and income), chronic diseases, and substance abuse was retrieved from public and medical re

298 Severely suicidal patients without substance abuse were randomly assigned to receive either

299 d risk assessment for unauthorised leave and substance abuse where its performance is relatively unte

300 interval [CI], 2.4- 17.5), those with active substance abuse within the past year (OR 2.2; 95% CI 1.4